Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
Insmed (INSM)
NASDAQ:INSM
Insmed (INSM) Stock Price & Analysis
513 Followers
INSM Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$18.31 - $32.00
Previous Close$24.77
Volume2.59M
Average Volume (3M)1.76M
Market Cap
$3.68B
Enterprise Value$4.09B
Total Cash (Recent Filing)$785.94M
Total Debt (Recent Filing)$1.20B
Price to Earnings (P/E)-4.7
Beta0.60
Next Earnings
Aug 01, 2024EPS Estimate
-$1.14Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-5.24
Shares Outstanding148,604,548
10 Day Avg. Volume1,832,368
30 Day Avg. Volume1,763,550
Standard Deviation0.14
R-Squared0.12
Alpha-0.00313
Financial Highlights & Ratios
Price to Book (P/B)-5.62
Price to Sales (P/S)15.00
Price to Cash Flow (P/CF)-5.10
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/Revenue14.57
Enterprise Value/Gross Profit21.51
Enterprise Value/Ebitda-6.52
Forecast
1Y Price Target
$46.25Price Target Upside86.72% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering13
Insmed News
PremiumCompany Announcements
Insmed Shareholders Approve Directors and Key Proposals
PremiumPre-Earnings
Is INSM a Buy, Before Earnings?
Bulls Say, Bears Say
Bulls Say
Analyst's ConfidenceAnalyst sentiment suggests significant stock re-rating potential on the back of favorable ASPEN trial results for brensocatib.
Clinical Trials And Revenue GrowthAnticipated success in the Phase 3 ASPEN trial for brensocatib could lead to significant revenue growth.
Drug Development And Market PotentialInsmed's TPIP is considered a potential 'category killer' with advantages in dosing, tolerability, and efficacy over current treatments.
Bears Say
Clinical Trial ConcernsThe Phase 2 TPIP trial in PH-ILD patients is small with only 39 participants, making it difficult to extrapolate the results to a larger population.
Market CompetitionMerck's Winrevair is anticipated to fundamentally change the PAH landscape, which could affect TPIP's positioning in the market.
Regulatory ChallengesThe PMDA in Japan will not consider label expansion based on ARISE data alone, highlighting regulatory challenges in one of INSM's key markets.
---
Ownership Overview
6.67% Insiders
35.15% Mutual Funds
53.77% Other Institutional Investors
4.41% Public Companies and Individual Investors
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
INSM FAQ
What was Insmed’s price range in the past 12 months?
Insmed lowest stock price was $18.31 and its highest was $32.00 in the past 12 months.
What is Insmed’s market cap?
Currently, no data Available
When is Insmed’s upcoming earnings report date?
Insmed’s upcoming earnings report date is Aug 01, 2024 which is in 75 days.
How were Insmed’s earnings last quarter?
Insmed released its earnings results on May 09, 2024. The company reported -$1.06 earnings per share for the quarter, beating the consensus estimate of -$1.238 by $0.178.
Is Insmed overvalued?
According to Wall Street analysts Insmed’s price is currently Undervalued.
Does Insmed pay dividends?
Insmed does not currently pay dividends.
What is Insmed’s EPS estimate?
Insmed’s EPS estimate is -$1.14.
How many shares outstanding does Insmed have?
Insmed has 148,604,550 shares outstanding.
What happened to Insmed’s price movement after its last earnings report?
Insmed reported an EPS of -$1.06 in its last earnings report, beating expectations of -$1.238. Following the earnings report the stock price went up 1.462%.
Which hedge fund is a major shareholder of Insmed?
Among the largest hedge funds holding Insmed’s share is Baker Bros Advisors LP. It holds Insmed’s shares valued at 9M.
---
Insmed Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$46.25 (86.72% Upside)
$46.25 (86.72% Upside)
Blogger Sentiment
Bullish
INSM Sentiment 100%
Sector Average 70%
Sector Average 70%
Hedge Fund Trend
Decreased
By 117.0K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $1.1M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Positive
Last 7 Days ▲ 2.8%
Last 30 Days ▲ 16.5%
Last 30 Days ▲ 16.5%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Negative
20 days / 200 days
Momentum
33.45%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
-23.63%
Trailing 12-Months
Company Description
Insmed
Insmed, Inc. is a biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases. Its first commercial product is ARIKAYCE (amikacin liposome inhalation suspension), which is approved in the United States for the treatment of Mycobacterium avium complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options. The MAC lung disease is a rare and often chronic infection that can cause irreversible lung damage and can be fatal. Its earlier-stage clinical pipeline includes INS1007, a novel oral reversible inhibitor of dipeptidyl peptidase 1 with therapeutic potential in non-cystic fibrosis bronchiectasis and other inflammatory diseases, and INS1009, an inhaled formulation of a treprostinil prodrug that may offer a differentiated product profile for rare pulmonary disorders, including pulmonary arterial hypertension. The company was founded in 1988 and is headquartered in Bridgewater, NJ.
---
INSM Company Deck
---
INSM Earnings Call
Q1 2024
0:00 / 0:00
---
INSM Stock 12 Month Forecast
Average Price Target
$46.25
▲(86.72% Upside)
Technical Analysis
Medicinova
―
Karyopharm Therapeutics
―
Crispr Therapeutics AG
―
Corvus Pharmaceuticals
―
Best Analysts Covering INSM
1 Year
1 Year Success Rate
11/18 ratings generated profit
1 Year Average Return
+18.48%
reiterated a buy rating 9 days ago
Copying Graig Suvannavejh's trades and holding each position for 1 Year would result in 61.11% of your transactions generating a profit, with an average return of +18.48% per trade.
---